LEGN (Legend Biotech) Earnings per share growth rate in current year

Corporate emblem and logo of Legend Biotech Corp. (LEGN)

Legend Biotech is integrating ESG principles into the development of gene therapies by minimizing laboratory waste. On GURU.Markets, the distribution of annual earnings per share changes reflects stability dynamics, where 95.30 indicates the value of this parameter. Global alliances ensure capital inflows, transitioning innovations into a stage of stable earnings. Distribution and testing efficiency is maintained through the engagement of external contractors.

LEGN: Legend Biotech Corp Earnings per share growth in current year 07/04/2022 - 11/10/2026

Financial and market metric breakdowns for Legend Biotech (LEGN)

- price and consensus price forecast:
Stock Quotes Legend Biotech Corp|LEGN - Analyst Consensus Forecast
- business market valuation indicators:
Market Value Legend Biotech Corp.|LEGN - Total Company Value
- balance sheet equity data:
Net Assets per Single Share Legend Biotech|LEGN - Company Book Value|Market Value to Book Value Ratio legendbiotech.com|LEGN - Cumulative Company Assets
- debt and liquidity details:
All Debt to Shareholders' Equity Ratio Legend Biotech|LEGN - Long-Term Debt to Capital|Short-Term Indebtedness to Equity legendbiotech.com|LEGN - Company Aggregate Debts|Debts to Book Value Legend Biotech Corp.|LEGN - Company Long-Term Debt|Company Short-Term Indebtedness Legend Biotech|Immediate Liquidity legendbiotech.com
- earnings and valuation multiples information:
LEGN - Net Income|Expected Net Income Legend Biotech|LEGN - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Legend Biotech Corp.|LEGN - PEG Multiple|Business Value to Operating Income Before Depreciation Legend Biotech Corp.|LEGN - Operating profit EBITDA|Net earnings per one share for the last twelve months Legend Biotech|LEGN - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months legendbiotech.com|LEGN - Earnings growth in current year|Earnings growth forecast for next year Legend Biotech
Fundamental valuation:LEGN Legend Biotech Corp
Manufactured products of Legend Biotech

This indicator measures the year-over-year dynamics of net income per ordinary share, reflecting the pace of business scaling through the percentage change in earnings. By analyzing the annual growth of earnings per share, an investor assesses the commercialization efficiency of Legend Biotech (LEGN) drugs, noting that regulatory barriers for gene therapy and dependence on Johnson & Johnson may temporarily constrain the positive momentum of this metric.

Main competitors

Net earnings per share growth this year Sana Biotechnology Inc|AUTL (Autolus Pharma) - Earnings growth in current year|Earnings per share growth rate in current year Allogene Corp ALLO|Earnings per share growth in current year Cartesian Therapeutics (RNAC)|Earnings per share growth in current year CLLS (cellectis.com)|Earnings per share growth in current year Caribou Biosciences, Inc. CRBU|Instil Bio Inc. - Earnings per share growth in current year|GNTA: Net earnings per share growth this year|Earnings per share increase in current year IPSC (Century Therapeutics)|JSPR: Earnings growth in current year|Net earnings per share change in current year Senti Biosciences SNTI|ADAP (Adaptimmune Therapeutics plc) - Earnings growth in current year|Earnings per share growth rate in current year CERo Therapeutics Holdings Inc. CERO|Earnings per share growth in current year Alaunos Therapeutics (TCRT)|achillestx.com - Earnings per share growth this year|Earnings growth in current year CRGX (CARGO Therapeutics)|poseida.com (PSTX) - Earnings per share growth rate in current year|TSVT: Net earnings per share growth this year|Earnings per share increase in current year GRCL (Gracell Bio)